Prostate Cancer Therapeutics Market Report 2026

Prostate Cancer Therapeutics Market Overview

• Prostate Cancer Therapeutics market size has reached to $12.88 billion in 2025 • Expected to grow to $19.25 billion in 2030 at a compound annual growth rate (CAGR) of 8.4% • Growth Driver: Surge In Prostate Cancer Incidences Fueling The Growth Of The Market Due To Aging Population And Increased Life Expectancy • Market Trend: Launch Of India's First Oral Once-A-Day Pill For Advanced Prostate Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Prostate Cancer Therapeutics Market?

Prostate cancer therapeutics refer to the range of medical treatments and interventions used to manage, control, or eliminate prostate cancer, a type of cancer that develops in the prostate gland of men. These therapies aim to slow disease progression, relieve symptoms, improve quality of life, and, in some cases, achieve remission. The main types of therapies in prostate cancer therapeutics are hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and others. Hormonal therapy is a medical treatment that alters hormone levels in the body to manage or treat certain conditions, like cancer or hormonal imbalances. It includes various drug classes such as androgen receptor inhibitors, GnRH receptor antagonists, PARP inhibitors, immune checkpoint inhibitors, and others administered orally or through injection. These therapies are distributed through hospital pharmacies, retail pharmacies, and online sales, catering to various end users such as clinics, hospitals, and others.

What Is The Prostate Cancer Therapeutics Market Growth Forecast?

The prostate cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $19.25 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to precision oncology adoption, biomarker-driven therapies, growth in oral oncology drugs, expanding immunotherapy pipeline, rising healthcare expenditure. Major trends in the forecast period include growing adoption of targeted therapies, rising use of parp inhibitors, expansion of immunotherapy in oncology, shift toward oral cancer drugs, precision medicine-based treatment selection.

Global Prostate Cancer Therapeutics Market Segmentation

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies 2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes 3) By Route Of Administration: Oral, Injectable 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies 5) By End User: Clinics, Hospitals, Other End Users Subsegments: 1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors 2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens 3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines 4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy 5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

What Is The Driver Of The Prostate Cancer Therapeutics Market?

The increasing incidence of prostate cancer is expected to propel the growth of the prostate cancer therapeutics market going forward. Prostate cancer is a disease in which malignant cells form in the tissues of the prostate gland, typically affecting older men. The incidence of prostate cancer is increasing due to the aging population, as the risk of developing the disease rises significantly with age, and longer life expectancy leads to more men living long enough to create it. Prostate cancer therapeutics help manage the disease by targeting cancer cells, slowing progression, and improving quality of life through treatments such as surgery, radiation, hormone therapy, and newer options like immunotherapy. For instance, in January 2025, according to Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, the number of men diagnosed with prostate cancer increased from 50,751 cases in 2022 to 55,033 cases in 2023. Therefore, the increasing incidence of prostate cancer is driving the growth of the prostate cancer therapeutics industry.

Key Players In The Global Prostate Cancer Therapeutics Market

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol‑Myers Squibb Company, F. Hoffmann‑La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Global Prostate Cancer Therapeutics Market Trends and Insights

Major companies operating in the prostate cancer therapeutics market are focusing on advancing innovative therapeutics, such as an oral once-a-day pill for advanced prostate cancer, to improve patient compliance and overall treatment outcomes. The oral once-a-day pill for advanced prostate cancer refers to treatments that are taken daily to manage metastatic castration-resistant prostate cancer by inhibiting testosterone's effects on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based company, launched Rexigo, India's first oral once-a-day pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies rapidly suppresses testosterone, helping control cancer growth while offering a better cardiovascular safety profile. It is an oral therapy, eliminating the need for injectable treatments that require administration by healthcare providers, thus offering greater patient convenience. This launch represents a significant advancement in prostate cancer management in India, providing patients and doctors with a new, convenient, safe, cost-effective treatment option.

What Are Latest Mergers And Acquisitions In The Prostate Cancer Therapeutics Market?

In June 2024, AstraZeneca plc, a UK-based pharmaceutical and biotechnology company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. With this acquisition, AstraZeneca aims to accelerate the development of next-generation radio conjugates to transform cancer treatment by delivering more targeted therapies that can replace traditional chemotherapy and radiotherapy regimens. Fusion Pharmaceuticals is a Canada-based clinical-stage oncology company that offers prostate cancer therapies, specifically targeting metastatic castration-resistant prostate cancer (mCRPC).

Regional Insights

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market consists of revenues earned by entities by providing services such as medical consultation services, diagnostic services, psychosocial support, clinical trials access, and genetic counseling and testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer therapeutics market also includes sales of hormone therapy medications, chemotherapy drugs, immunotherapy products, and targeted therapy drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prostate Cancer Therapeutics Market Report 2026?

The prostate cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.